March 25th 2025
During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory multiple myeloma.
The Black Swan Research Initiative® and a Paradigm Shift in the Treatment of Multiple Myeloma
January 21st 2014Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
Watch
Phase II Trial of Elderly Patients With Newly Diagnosed Multiple Myeloma
January 10th 2014MarÃa-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.
Watch
First-in-Class Targeted Agent Shows Activity in Refractory Multiple Myeloma
December 10th 2013According to data presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, a first-in-class targeted agent demonstrated activity in patients with relapsed and refractory multiple myeloma.
Read More
New Standard of Care Established in Newly Diagnosed Multiple Myeloma
December 9th 2013In patients with transplant-ineligible NDMM, the combination of continuous lenalidomide and low-dose dexamethasone (continuous Rd) extends PFS and trends toward improving OS compared with the standard combination of MPT.
Read More
Early Intervention in Smoldering Myeloma May Delay Progression
December 9th 2013CRs were seen in a group of high-risk patients following intervention in early or “smoldering†myeloma with a three-drug regimen, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.
Read More
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myeloma
October 19th 2013In an updated analysis of the phase III MM-003 trial, Celgene International Sarl, the makers of pomalidomide, reported on a new progression-free survival (PFS) analysis and final overall survival (OS) in September 2013.
Read More
Transforming Expectations and Outcomes With Targeted Therapies
October 18th 2013With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer
Read More
Pomalidomide Labeled an Advance in Multiple Myeloma
December 9th 2012The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Read More